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Abstract
Background: The index of myocardial performance has prognostic power in patients with
cardiomyopathy and following myocardial infarction. As the index of myocardial performance has
been shown to be preload and afterload dependent, the effect of altering contractility on IMP and
its components with left ventricular dysfunction has been incompletely delineated.
Methods: Chronic left ventricular dysfunction was induced in 10 canines using coronary
microsphere embolization. Each dog was instrumented and imaged with 2D echo and Doppler. At
the same atrially paced rate, contractility was increased with a dobutamine infusion and then
following 4 weeks of oral digoxin.
Results: With chronic left ventricular dysfunction, a reduced left ventricular ejection fraction (42
± 3%, p < 0.001) and increased index of myocardial performance (0.58 ± 0.17, p < 0.01) due to
isovolumic contraction time lengthening and shortened left ventricular ejection time were noted.
Dobutamine increased ejection fraction (p < 0.001), reduced left ventricular end diastolic pressure
(p < 0.01), and reduced the index of myocardial performance (0.33 ± 0.17, p < 0.001) due to
isovolumic contraction time, isovolumic relaxation time, and left ventricular ejection time
shortening. Digoxin increased ejection fraction (p < 0.05), reduced left ventricular end diastolic
pressure (p < 0.05), and reduced the index of myocardial performance (0.42 ± 0.13, p < 0.01) due
to isovolumic contraction time shortening (p < 0.001). Both dobutamine and digoxin lengthened
the diastolic filling period (p < 0.01).
Conclusion: Increased inotropy with digoxin and dobutamine reduced the index of myocardial
performance in dogs with left ventricular dysfunction. Shortened isovolumic contraction time,
increased diastolic filling period, and reduced left ventricular end diastolic pressure with digoxin
may provide insight into its efficacy in heart failure.
Background
The index of myocardial performance (IMP), calculated as
the sum of the isovolumic relaxation time (IRT) and iso-
volumic contraction time (ICT) divided by the left ven-
tricular (LV) ejection time (LVET), has been utilized as a
combined systolic-diastolic index that is prognostic in
patients with dilated cardiomyopathy [1] and post myo-
cardial infarction [2]. Its predictive value appears to be
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related to shorter isovolumic indices and preserved LV
ejection time (LVET). In the original description of this
index in patients with normal LV function and dilated car-
diomyopathy, IMP was correlated with indices of systolic
performance and contractility but was unrelated to heart
rate, preload, and mean arterial pressure [3]. It has been
further demonstrated that contractility and systolic per-
formance were related to IMP in studies which utilize
dobutamine in the normal left ventricle [4,5], in the left
ventricle with reduced LV function [6,7] with contractile
reserve, with the ischemic production of LV dysfunction
[8], or in groups with differing LV function [1,3]. Of
importance, dobutamine was demonstrated to shorten all
components of IMP but specifically ICT and prolonged
the diastolic filling period both in the normal ventricle [5]
and in the left ventricle with dysfunction and contractile
reserve [6,7].
Systematic evaluations of IMP in the normal and abnor-
mal left ventricle have recently been performed using a
canine model of chronic ischemic LV dysfunction. IMP
was demonstrated to be preload and afterload dependent
but not heart rate dependent [9,10]. In this model,
improved systolic performance with afterload reduction
with LV dysfunction was associated with shortening of the
isovolumic indices and lengthening of the LVET [12].
Although clinical studies [6,7] have been performed
assessing the effect of dobutamine stress on IMP with LV
dysfunction, the focus has been on ischemia or contractile
reserve. Limited work has been performed assessing the
effect of contractility on IMP and its components with LV
dysfunction without the obfuscating effects of intraven-
tricular conduction delay or ischemic provocation [6,7].
Digoxin, an oral inotropic agent, also has beneficial symp-
tomatic effects in heart failure patients with either reduced
or preserved LV function [11]. However, the influence of
digoxin on IMP is unknown and may provide some
insight into its efficacy.
The goals of this study were: [1] to determine the effects of
increased contractility on IMP and its components; and
[2] to determine whether digoxin, a weak inotrope with-
out an adverse survival benefit, affects IMP and its compo-
nents. With LV dysfunction, we hypothesize that inotropic
agents reduce the IMP by shortening isovolumic indices
and possibly lengthening LVET (due to increased stroke
volume) with a resultant increase in diastolic filling
period. To assess this hypothesis, we used a canine model
of chronic ischemic LV dysfunction producing only mild
systolic dysfunction with elevated LV filling pressures
where ischemia with inotropic stimulation was unlikely.
Methods
The animals used in this study were maintained in accord-
ance with the guidelines of the Committee on Animal
Studies at Wayne State University School of Medicine and
with the position of the American Heart Association on
research animal use. The protocol was approved by the
Animal Investigation Committee of Wayne State Univer-
sity. Anesthesia was induced in 10 conditioned mongrel
dogs (16–24 kg) with intramuscular morphine sulfate
(1.5 mg/kg) and acepromazine (1.1 mg/kg) followed in
15 minutes by 30 mg/kg of intravenous ketamine hydro-
chloride. Maintenance anesthesia was produced by intra-
venous morphine sulfate (1.5 mg/kg/hr) and
pentobarbital (3 mg/kg/hr). The dogs were intubated and
artificially ventilated with a Harvard respirator using
room air. Using fluoroscopic guidance, two 7F high fidel-
ity catheters (Millar Instruments) were introduced via the
right carotid artery and advanced to the left ventricle and
ascending aorta. A #7 multipurpose Judkins catheter was
introduced through a sheath (Cordis) into the right femo-
ral artery and advanced into the left coronary ostium.
Continuous electrocardiographic monitoring was per-
formed using lead II. At held end expiration, ECG, LV
pressures, dP/dT, and central aortic pressures were
obtained at 100 mm/s using an 8 channel physiologic
recorder (Gould). Simultaneous 2 dimensional echocar-
diograms and Doppler were obtained from with the use of
a phased array echocardiograph (Aloka 880). Trans-
esophageal 4 chamber view was obtained from a 5 MHz
probe placed in the mid-esophagus. Both transaortic and
transmitral pulsed Doppler recordings were obtained
from the LV outflow tract and from beyond the tips of the
mitral leaflets in the left ventricle at 100 mm/s. Mitral
regurgitation was assessed from the 4-chamber view as the
size of the maximal color flow jet divided by the left atrial
area.
Induction of LV dysfunction
Ischemic LV dysfunction was induced by left main coro-
nary artery plastic microsphere injections (58 ± 2
microns) (3M) injected in boluses of 17,500 micro-
spheres every 5–10 minutes until the peak positive dP/dT
was reduced by 25% and the LV end diastolic pressure was
>12 mm Hg. LV dysfunction (LV ejection fraction = 35–
40% acutely and >40% chronically) was produced in 45–
60 minutes with only mild mitral regurgitation (maximal
color flow jet area/left atrial area <20%). This approach
ultimately leads to a model of chronic LV dysfunction
where the extent of LV dysfunction may be titrated [12].
Following 45 minutes of stable hemodynamics, the above
parameters were repeated. The right carotid and femoral
arteries were repaired and the dogs were allowed to
recover without any dog succumbing. The dogs were fol-
lowed carefully for 8 weeks prior to re-study. This time
period was chosen as this model has previously demon-
Cardiovascular Ultrasound 2006, 4:45 http://www.cardiovascularultrasound.com/content/4/1/45
Page 3 of 8
(page number not for citation purposes)
strated interstitial and replacement fibrosis without evi-
dence of necrosis or inflammation at 8 weeks post
embolization [12].
At 8 weeks post coronary microsphere embolization, the
animals were anaesthetized, intubated, instrumented, and
ventilated as above. Using fluoroscopy, a #7 thermodilu-
tion catheter and a #5 bipolar pacing wire were advanced
from the left internal jugular vein to the pulmonary artery
and right atrium respectively. Atrial pacing commenced
10 beats above baseline rate with a PR interval <160 msec.
Transthoracic and transesophageal echocardiography and
Doppler were obtained as above. Continuous electrocar-
diographic monitoring was performed using lead II. The
above hemodynamic, echocardiographic, and Doppler
parameters were obtained after 10 minutes of steady state
atrial pacing. Dobutamine was infused at a rate of 2–2.5
micrograms/kg/minute for 15 minutes. Care was taken to
adjust the rate of infusion to ensure that atrial pacing was
maintained. The above parameters were then obtained.
The infusion was discontinued and the dogs were
observed until hemodynamics and echocardiographic
assessment of LV systolic function returned to the pre-
dobutamine LV dysfunction baseline. The above parame-
ters were then obtained as a baseline for digoxin therapy.
The vessels were repaired, and the animals were recovered.
On the following day, each dog received 0.02 mg/kg/dig-
oxin in their food daily to a maximal dose of 0.25 mg dig-
oxin for 4 weeks [13,14]. At 1 and 2 weeks, digoxin levels
were ascertained to ensure that blood levels were non-
toxic. After 4 weeks of therapy, the animals were anaesthe-
tized, intubated, ventilated, and instrumented as above.
Atrial pacing commenced at the same rate as with dob-
utamine and hemodynamics, echocardiography and Dop-
pler were obtained as above. The animals were then
sacrificed.
Control dogs
LV dysfunction was induced in 8 additional dogs as
described above. At 8 and 12 weeks post embolization,
the dogs were instrumented as described above. Hemody-
namics, echocardiography, spectral, and color Doppler
were obtained at baseline and with atrial pacing 10 beats
above baseline. The same atrial rate was used for each dog
at 8 and 12 weeks post embolization.
Hemodynamic, echocardiographic, and transmitral 
Doppler measurements
For all stages and time periods, LV pressures, dP/dT, car-
diac outputs, and aortic pressures were measured from the
average of 3 consecutive cycles at held end expiration. The
time constant of LV pressure decline was calculated using
the Weiss method [15]. LV end diastolic and end systolic
volumes were calculated using Simpson's Rule from the
average of 3 determinations. LV ejection fraction was cal-
culated as the difference between end diastolic volume
and end systolic volume divided by end diastolic volume.
LV mass was calculated by the area length method as per
the recommendations of the American Society of Echo
[16].
For all stages and time periods, all Doppler indices were
measured from the average of 3 consecutive cycles at held
end expiration. From transmitral Doppler indices, peak
rapid filling velocity (E) and peak atrial filling velocity (A)
were measured. The E/A ratio was calculated. The rapid
filling deceleration time was calculated as the time inter-
val from the peak rapid filling velocity to the time mitral
flow decelerated to the zero baseline. The tracing was
extrapolated to the zero baseline if atrial filling com-
menced prior to mitral flow fully decelerating to zero.
Diastolic, rapid filling, and atrial filling velocity integrals
were determined. Mitral regurgitation was assessed using
the ratio of the maximal color flow jet area in the left
atrium during systole divided by the left atrial area.
Index of myocardial performance
From the transmitral pulsed Doppler, the time interval
between the end of mitral filling and the onset of mitral
filling was determined ("a"). From transaortic pulsed
Doppler, the time interval from the beginning of aortic
flow to the end of aortic flow was determined ("b" or
LVET). The IMP can be calculated as
IMP = (a-b)/b
To determine the IRT, the time from the R wave to the end
of aortic flow was subtracted from the R wave to the onset
of mitral flow interval. As "a-b" represents total isovolu-
mic time, the ICT is the difference between IRT and "a-b"
[3]. The ICT, IRT, and LVET indexes were calculated to cor-
rect for differing heart rates by dividing the value by the
square root of the RR interval (for non-paced compari-
sons).
Intraobserver variability for calculation of IMP was deter-
mined from 25 randomly selected stages. Each determina-
tion was performed 4 weeks apart. The average difference
between determinations was 0.008 ± 0.002. Intraobserver
and interobserver variability for LV echocardiographic
volume was determined by selecting end diastolic and
end systolic frames from the echocardiogram of 10 previ-
ously studied dogs. Each frame was analyzed 3 weeks
apart by 2 observers (see acknowledgement). The average
difference for end diastolic or end systolic volume was 2.2
± 0.9 cc for intraobserver variability and 3.4 ± 1.7 cc for
interobserver variability.
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Statistics
All data was expressed as mean ± standard deviation. Dif-
ferences between a variable among stages was assessed
using paired T testing. A p < 0.05 was considered to be sig-
nificant.
Results
Table 1 summarizes the hemodynamics, LV size and func-
tion parameters, transmitral Doppler and IMP at baseline
and with chronic LV dysfunction. With chronic LV dysfunc-
tion, LV volumes, LV mass, heart rate, and LV end diastolic
pressure were increased. Ejection fraction and peak +dP/
dT declined. Parameters of relaxation (Tau and E/A) were
also abnormal as compared to baseline. The deceleration
time was also shortened suggesting reduced LV chamber
compliance. This finding may be secondary to the intersti-
tial and replacement fibrosis seen in the myocardium with
this model of chronic LV dysfunction [12]. IMP was
increased as compared to baseline (Figure 1) due to insig-
nificant prolongation of IRT (p = 0.18), prolongation of
ICT, and LVET shortening. At baseline, 2 of 10 dogs had
trivial mitral regurgitation (jet area/left atrial area <5%).
With LV dysfunction, 3 dogs had trivial or mild mitral
regurgitation (jet area/left atrial area = 4%, 5%, and 8%).
Table 2 summarizes the above parameters with paced LV
dysfunction and for dobutamine infusion. As expected,
dobutamine increased peak +dP/dT, stroke volume, and
ejection fraction with a reduction in LV end diastolic pres-
sure. Dobutamine improved LV relaxation and LV cham-
ber compliance (as characterized by lengthening of the
deceleration time). IMP declined (Figure 2) due to
marked shortening of the ICT, shortening of IRT, and
shortening of LVET. Mitral regurgitation was noted in 1 of
10 dogs with dobutamine (jet area/left atrial area = 6%)
Table 3 summarizes the above parameters with paced LV
dysfunction and with digoxin administration. Digoxin
administration resulted in an increased LV ejection frac-
tion, stroke volume, and peak +dP/dT associated with a
decline in LV end diastolic pressures. The diastolic filling
period prolonged without change in other diastolic func-
tion parameters measured. IMP declined in 9 of 10 dogs
(Figure 3) primarily secondary to ICT shortening (>60%
reduction). Mitral regurgitation was noted in 2 dogs with
digoxin (jet area/left atrial area = 5%, 6%). Table 4 sum-
marizes the hemodynamics, LV size and function param-
eters, transmitral Doppler and IMP 8 and 12 weeks post
embolization. There were no significant differences
between parameters measured at 8 and 12 weeks in con-
trol dogs strongly supporting the stability of this model.
Mitral regurgitation was seen in 1 of 8 dogs at both 8 and
12 weeks (jet area/left atrial area = 5% at 8 weeks and 4%
at 12 weeks post embolization).
Discussion
IMP has been identified as a useful prognostic parameter
following acute myocardial [2,17,18] infarction, with
dilated cardiomyopathy [1], amyloid heart disease [19],
and pulmonary hypertension [20]. Its prognostic capabil-
ities appear to be mediated by increased values due to
longer isovolumic indices and a shorter LVET. Despite its
apparent clinical performance, IMP is preload and after-
The Effect of chronic LV dysfunction on IMP:The IMP is plot-ted for each dog (y axis) at baseline (base) and following the development f chronic LV dysfu ction (LV Dys)Figure 1
The Effect of chronic LV dysfunction on IMP: The IMP is plot-
ted for each dog (y axis) at baseline (base) and following the 
development of chronic LV dysfunction (LV Dys). With 
chronic LV dysfunction, each dog demonstrated an increase 
IMP.
Stage
IM
P
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Base LV Dys
p=0.0062
Table 1: Hemodynamics, LV size, transmitral and transaortic 
Doppler, and IMP at baseline and with chronic LV dysfunction
Baseline Chronic LVD
LV End Diastolic Volume (cc) 41 ± 5 54 ± 8***
LV End Systolic Volume (cc) 15 ± 4 31 ± 12***
Stroke Volume (cc) 26 ± 3 23 ± 9
LV Ejection fraction (%) 63 ± 9 42 ± 3***
LV Mass (g) 61 ± 10 85 ± 11***
LVSP (mm Hg) 109 ± 14 111 ± 12
LVEDP (mm Hg) 6.2 ± 2.3 11.8 ± 4.9**
Cardiac Output (l/min) 3.1 ± 0.7 2.8 ± 0.4
Peak +dP/dT (mm Hg/sec) 1874 ± 244 1388 ± 206***
Tau (msec) 24 ± 6 39 ± 5***
E/A 2.1 ± 1.3 1.5 ± 0.4*
Heart rate (beats/min) 78 ± 12 93 ± 18*
Deceleration Time (msec) 217 ± 38 129 ± 36**
ICT index (msec) 40 ± 22 58 ± 31*
IRT index (msec) 46 ± 19 63 ± 29
LV ejection time index (msec) 226 ± 23 201 ± 24*
IMP 0.38 ± 0.14 0.60 ± 0.19**
Abbreviations: E/A = peak rapid filling velocity/peak atrial filling 
velocity; ICT = isovolumic contraction time; IRT = isovolumic 
relaxation time; IMP = Index of myocardial performance; LVSP = LV 
systolic pressure; LVD = LV dysfunction; LVEDP = LV end diastolic 
pressure.
Statistics:*p < 0.05, **p < 0.01, ***p < 0.001 vs Baseline;
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Table 4: Hemodynamics, parameters of LV size, transmitral and 
transaortic Doppler and IMP at paced LV dysfunction: 8 and 12 
weeks post embolization
Paced LV 
Dysfunction-8 
Weeks
Paced LV 
Dysfunction-12 
Weeks
LV End Diastolic Volume (cc) 54 ± 7 55 ± 6
LV End Systolic Volume (cc) 32 ± 12 33 ± 9
Stroke Volume (cc) 22 ± 8 22 ± 7
LV Ejection fraction (%) 43 ± 4 42 ± 4
LVSP (mm Hg) 116 ± 13 119 ± 21
MAP (mm Hg) 104 ± 15 105 ± 13
LVEDP (mm Hg) 11.3 ± 2.4 11.2 ± 2.0
Peak +dP/dT (mm Hg/sec) 1439 ± 289 1451 ± 184
Tau (msec) 36 ± 4 34 ± 8
E (cm/s) 78 ± 19 82 ± 15
A (cm/s) 54 ± 9 56 ± 13
E/A 1.8 ± 0.7 1.8 ± 0.5
Heart rate (beats/min) 102 ± 7 102 ± 7
DFP (msec) 311 ± 44 314 ± 46
Deceleration Time (msec) 151 ± 29 149 ± 36
ICT index (msec) 57 ± 25 54 ± 22
IRT index (msec) 58 ± 27 59 ± 19
LV ejection time index (msec) 201 ± 22 197 ± 25
IMP 0.58 ± 0.19 0.57 ± 0.17
Abbreviations: see table 2
Table 3: Hemodynamics, parameters of LV size, transmitral and 
transaortic Doppler, and IMP with LV Dysfunction and with 
digoxin
Paced LV Dysfunction Digoxin
LV End Diastolic Volume (cc) 54 ± 7 52 ± 8
LV End Systolic Volume (cc) 31 ± 10 25 ± 5*
Stroke Volume (cc) 23 ± 7 27 ± 7*
LV Ejection fraction (%) 43 ± 4 52 ± 8*
LVSP (mm Hg) 112 ± 14 118 ± 17
MAP (mm Hg) 101 ± 10 105 ± 12
LVEDP (mm Hg) 11.6 ± 2.1 8.6 ± 2.7*
Peak +dP/dT (mm Hg/sec) 1456 ± 288 1889 ± 146**
Tau (msec) 36 ± 7 33 ± 8
E (cm/s) 83 ± 22 82 ± 15
A (cm/s) 56 ± 17 59 ± 14
E/A 1.9 ± 0.8 1.7 ± 0.7
Heart rate (beats/min) 102 ± 7 102 ± 7
DFP (msec) 296 ± 54 340 ± 42**
DVI (cm) 12.5 ± 2.0 14.1 ± 2.4*
Deceleration Time (msec) 151 ± 34 149 ± 31
ICT index (msec) 57 ± 34 23 ± 19***
IRT index (msec) 61 ± 26 58 ± 19
LV ejection time index (msec) 204 ± 18 194 ± 19
IMP 0.58 ± 0.15 0.42 ± 0.13**
Abbreviations: see table 2
Statistics: *p < 0.05, **p < 0.001, ***p < 0.001 vs Paced LV Dysfunction
Table 2: Hemodynamics, parameters of LV size, transmitral and 
transaortic Doppler, and IMP with LV dysfunction and with 
dobutamine
Paced LV 
Dysfunction
Dobutamine
LV End Diastolic Volume (cc) 55 ± 7 51 ± 8
LV End Systolic Volume (cc) 32 ± 7 18 ± 5***
Stroke Volume (cc) 23 ± 6 33 ± 7***
LV Ejection fraction (%) 42 ± 3 65 ± 10***
LVSP (mm Hg) 110 ± 12 109 ± 7
MAP (mm Hg) 100 ± 10 93 ± 9
LVEDP (mm Hg) 11.8 ± 2.4 7.5 ± 2.1**
Peak +dP/dT (mm Hg/sec) 1438 ± 279 2250 ± 148***
Tau (msec) 37 ± 6 25 ± 7***
E (cm/s) 81 ± 24 111 ± 16***
A (cm/s) 55 ± 29 54 ± 19
E/A 1.9 ± 0.7 2.3 ± 0.8
Heart rate (beats/min) 102 ± 7 102 ± 7
DFP (msec) 296 ± 54 364 ± 38***
DVI (cm) 12.6 ± 2.4 16.7 ± 2.5***
Deceleration Time (msec) 148 ± 30 201 ± 46**
ICT index (msec) 55 ± 30 17 ± 10***
IRT index (msec) 63 ± 25 44 ± 22*
LV ejection time index (msec) 204 ± 22 186 ± 28*
IMP 0.59 ± 0.17 0.33 ± 0.17***
Abbreviations: see table 1; A = peak atrial systolic velocity; DFP = 
diastolic filling period; DVI = diastolic velocity integral; E = peak rapid 
filling velocity; MAP = mean arterial pressure.
Statistics: *P < 0.05, **p < 0.01, ***p < 0.001 vs Paced LV Dysfunction
The effect of dobutamine infusion on IMP with chronic LV dysfunction: The IMP is plotted for each dog (y axis) at paced LV dysfunction (LV Dys) a d foll wi g infusion of dob-utamin  (LV Dys-Dob)Fig re 2
The effect of dobutamine infusion on IMP with chronic LV 
dysfunction: The IMP is plotted for each dog (y axis) at paced 
LV dysfunction (LV Dys) and following infusion of dob-
utamine (LV Dys-Dob). With dobutamine infusion, each dog 
demonstrated a decline in IMP.
Stage
IM
P
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
P=0.0007
LV Dys LV Dys-Dob
Cardiovascular Ultrasound 2006, 4:45 http://www.cardiovascularultrasound.com/content/4/1/45
Page 6 of 8
(page number not for citation purposes)
load dependent based on changes in LVET and isovolumic
indices especially with LV dysfunction as previously
described using a canine model of chronic ischemic LV
dysfunction [9,10]. In this study, we assessed IMP and its
components in this same model of chronic LV dysfunc-
tion utilizing both an intravenous and oral agent that
increases contractility.
Both inotropic agents significantly increased peak +dP/dT
and LV ejection fraction though the effect of digoxin was
smaller. IMP was markedly reduced with dobutamine
infusion with reductions in both ICT and IRT despite a
reduction in LVET. The reduction in ICT was >70% and
due to a combination of prolongation of time to mitral
closure (12 msec) and shortening of time to onset of aor-
tic flow (18 msec). Similarly oral digoxin for 1 month
resulted in a reduction in the IMP due to a 61% reduction
in ICT. Shortening of the ICT was likely related to the pro-
longation of the time to mitral closure (24 msec). With
both agents, LV filling pressures declined and the diastolic
filling period increased suggesting that reductions in total
isovolumic time resulted in greater time for diastolic fill-
ing. With dobutamine, stroke volume increased and relax-
ation improved allowing a greater filling volume to enter
a more relaxed left ventricle with lower resultant filling
pressures. With digoxin, stroke volume also increased and
was associated with a longer diastolic filling period result-
ing in a lower LV filling pressure. This finding with dig-
oxin is intriguing as its use in patients with preserved LV
function (ejection fraction >40%) has been both advo-
cated and questioned [11,21].
Previous literature
Using a swine model, LaCorte [8] demonstrated that IMP
was related to changes in cardiac output, preload recruita-
ble stroke work, ejection fraction, and LV stiffness with
both normal LV function and following an ischemic
insult. In a pediatric population, dobutamine reduced
IMP and its components with the reduction in ICT being
the predominant change [5]. Broberg [4] demonstrated in
a mouse model of normal LV systolic function that IMP
correlated with peak +dP/dT using dobutamine. Tei [3], in
his original description, noted a significant relation of
ICT, LVET, and IMP to peak +dP/dT, and IRT to peak -dP/
dT in patients with normal LV function and cardiomyop-
athy patients. A systematic evaluation of contractility
requires a model of LV dysfunction in which a positive ino-
trope is administered or a negative inotrope administered
in a model with normal LV function.
However, the relationship between contractile alterations
and IMP is less well delineated in the left ventricle with
reduced LV function. Most information regarding the
effects of contractile alterations are based on an acute
ischemic episode from a normal resting LV function [8].
There are a few studies in patients with nonischemic
dilated cardiomyopathy and coronary disease patients
post myocardial infarction in which dobutamine reduced
IMP in patients with contractile reserve but not in patients
who were ischemic [6,7]. Individual IMP component
analysis was performed only by Duncan [7] who noted a
shortening of ICT and a lengthening of LVET in patients
with nonischemic dilated cardiomyopathy and left bun-
dle branch block undergoing dobutamine echocardiogra-
phy. However, a systematic assessment of the influence of
a contractile agent on IMP and its components in a model
of LV dysfunction has not been evaluated. Our study fills
that void and demonstrates that IMP declines with dob-
utamine and digoxin due to a marked reduction in ICT
using a model of mild LV dysfunction. As salutary effects
of digoxin have been demonstrated in several clinical tri-
als with preserved [9] and reduced LV ejection fractions
[11,22], the data in our trial may shed some light on a
potential mechanism of improvement seen in the DIG
trial. Not only did digoxin decrease IMP by virtue of
reducing the ICT, the diastolic filling period lengthened
and LV end diastolic pressure declined.
Limitations
As this is an experimental study, the applicability of these
findings and relation to intact humans is always a limita-
tion. The general anesthesia utilized may influence the
results. However, this anesthesia regimen has been uti-
lized in multiple experimental studies [9,10,12] and has
not reduced LV systolic function. Second, the use of dob-
utamine was always followed by digoxin administration
may have a generated a series effect. However, the acute
effects of dobutamine were evaluated first and the effect of
digoxin was evaluated after oral therapy several weeks
later. Baseline LV systolic and diastolic function parame-
Effect of digoxin on IMP with chronic LV dysfunctionFigure 3
Effect of digoxin on IMP with chronic LV dysfunction. The 
IMP is plotted for each dog (y axis) at paced LV dysfunction 
(LV Dys) and following infusion of dobutamine (LV Dys-Dig). 
With dobutamine infusion, 13 of 14 dogs demonstrated a 
decline in IMP.
Stage
IM
P
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
LV Dys LV Dys-Dig
p=0.038
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ters were virtually unchanged in control LV dysfunction
dogs with a similar degree of LV dysfunction at 8 and 12
weeks post embolization. Baseline LV dysfunction may
change over this time in this model but appears to be asso-
ciated with significant (moderate or greater) mitral regur-
gitation [14]. Third, the model of LV dysfunction used to
assess the IMP may not be applicable to all patients with
LV dysfunction. We believe that this model is applicable
as we used a coronary microsphere model of LV dysfunc-
tion which results in diffuse fibrotic changes throughout
the myocardium which bears great similarity to histopath-
ogy seen in diabetic cardiomyopathy [12,23], ischemic
cardiomyopathy, and hypertensive heart disease with LV
dysfunction. Finally, it is not clear that dobutamine or
digoxin might have similar effects on IMP and its compo-
nents with more severe LV dysfunction. As the LV ejection
fraction was <40% (moderate LV dysfunction) in several
animals, and the responses of IMP and ICT were uniform
in most dogs, it might be reasonable to expect that ino-
tropic stimulation with more severe LV dysfunction might
produce similar responses in IMP and ICT. However, spe-
cific evaluation of dogs with varying degrees of induced
LV dysfunction would be required.
Conclusion
Though IMP has been demonstrated to be load dependent
[9,10], it clearly reflects changes in the contractile state.
IMP, as a single parameter indicator describing a com-
bined systolic-diastolic index, may categorize LV function
and predict prognosis post myocardial infarction or with
dilated cardiomyopathy [1-3]. Its prognostic ability may
very well be based on shortening of ICT and lengthening
of LVET [1,2]. The major influence was on ICT in this
study, and ICT has also been demonstrated to decline
with afterload reduction [10]. A secondary finding was the
reduction in LV end diastolic pressure associated with pro-
longation of diastolic filling with both digoxin and dob-
utamine. In particular, digoxin reduced LV end diastolic
pressure to a similar degree as dobutamine but without
affecting LVET and IRT. As the ejection fraction was mildly
depressed secondary to coronary microsphere induced
micro-infarctions and fibrosis [12], it may have direct rel-
evance to patients with both ischemic and hypertensive
etiologies of LV dysfunction. The significance of the effect
of digoxin on the length of the diastolic filling period
needs further investigation in patients with heart failure
and preserved LV function.
In conclusion, the effect of increasing inotropic stimula-
tion in a model of mild chronic canine LV dysfunction
was determined. Increasing inotropy with digoxin and
dobutamine reduced IMP primarily due to ICT shorten-
ing. Dobutamine had the additional effects of IRT and
LVET shortening. Of note, a shortened ICT, increased
diastolic filling period, and reduced LV end diastolic pres-
sure with digoxin may provide insight into its efficacy in
heart failure.
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